Torisel (temsirolimus) is a small molecule pharmaceutical. Temsirolimus was first approved as Torisel on 2007-05-30. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat mantle-cell lymphoma and renal cell carcinoma. The pharmaceutical is active against serine/threonine-protein kinase mTOR. Torisel's patents are valid until 2032-05-10 (FDA).
|Indication||mantle-cell lymphoma, renal cell carcinoma|
|Drug Class||Immunosuppressives: immunosuppressant, rapamycin derivatives|